公开(公告)号：US12016836B2

公开(公告)日：2024-06-25

申请号：US18168128

申请日：2023-02-13

Applicant: Lapix Therapeutics, Inc.

Inventor： Anas M. Fathallah ,  Scott D. Larsen ,  Abdulraouf Ramadan

IPC: A61K31/198 ,  A61K9/00 ,  A61K9/08 ,  A61K31/357 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K47/40 ,  A61P25/28 ,  A61P37/06 ,  C07C235/34 ,  C07D213/65 ,  C07D217/02 ,  C07D235/06 ,  C07D319/18

CPC classification number: A61K31/198 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/357 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K47/40 ,  A61P25/28 ,  A61P37/06 ,  C07C235/34 ,  C07D213/65 ,  C07D217/02 ,  C07D235/06 ,  C07D319/18

Abstract: Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:




wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.

公开(公告)号：US11648225B2

公开(公告)日：2023-05-16

申请号：US17886926

申请日：2022-08-12

Applicant: Lapix Therapeutics, Inc.

Inventor： Anas M. Fathallah ,  Scott D. Larsen ,  Abdulraouf Ramadan

IPC: A61K31/198 ,  A61K47/40 ,  C07D319/18 ,  C07D217/02 ,  C07D213/65 ,  C07D235/06 ,  A61K31/357 ,  A61K31/472 ,  A61K31/44 ,  A61K31/4184 ,  A61P25/28 ,  A61P37/06 ,  A61K9/00 ,  A61K9/08 ,  C07C235/34

CPC classification number: A61K31/198 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/357 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K47/40 ,  A61P25/28 ,  A61P37/06 ,  C07C235/34 ,  C07D213/65 ,  C07D217/02 ,  C07D235/06 ,  C07D319/18

Abstract: Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:




wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.

公开(公告)号：US20240173389A1

公开(公告)日：2024-05-30

申请号：US18279612

申请日：2022-03-11

Applicant: LAPIX THERAPEUTICS, INC.

Inventor： Anas Fathallah ,  Abdulraouf Ramadan

IPC: A61K39/00 ,  A61K9/00 ,  A61K9/127 ,  A61K31/198 ,  A61K31/661 ,  A61K45/06 ,  A61P37/06

CPC classification number: A61K39/0008 ,  A61K9/0019 ,  A61K9/127 ,  A61K31/198 ,  A61K31/661 ,  A61K45/06 ,  A61P37/06 ,  A61K2039/55555

Abstract: Provided herein are compositions comprising amino acids, e.g., hydroxyamino acids, thioamino acids, or pharmaceutically acceptable salts thereof, that can be used to reduce immune intolerance in a subject. The compositions can be used, for example, to treat autoimmune disorders or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy.

公开(公告)号：US20240351977A1

公开(公告)日：2024-10-24

申请号：US18579943

申请日：2022-08-12

Applicant: Lapix Therapeutics, Inc.

Inventor： Anas M. Fathallah ,  Scott D. Larsen ,  Abdulraouf Ramadan

IPC: C07C237/12 ,  A61K9/127 ,  A61K39/00 ,  A61K39/39 ,  C07C271/22 ,  C12N15/86

CPC classification number: C07C237/12 ,  A61K9/127 ,  A61K39/39 ,  C07C271/22 ,  C12N15/86 ,  A61K2039/542 ,  A61K2039/55555 ,  C12N2750/14143

Abstract: Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula: wherein values for the variables (e.g., X, R) are as described herein.

公开(公告)号：US20230089267A1

公开(公告)日：2023-03-23

申请号：US17886926

申请日：2022-08-12

Applicant: Lapix Therapeutics, Inc.

Inventor： Anas M. Fathallah ,  Scott D. Larsen ,  Abdulraouf Ramadan

IPC: A61K31/198 ,  C07C235/34 ,  C07D319/18 ,  C07D217/02 ,  C07D213/65 ,  C07D235/06 ,  A61K31/357 ,  A61K31/472 ,  A61K31/44 ,  A61K31/4184 ,  A61P25/28 ,  A61P37/06 ,  A61K9/00 ,  A61K9/08 ,  A61K47/40

Abstract: Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula: wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.

公开(公告)号：US20240299327A1

公开(公告)日：2024-09-12

申请号：US18659715

申请日：2024-05-09

Applicant: LAPIX Therapeutics, Inc.

Inventor： Anas M. Fathallah ,  Scott D. Larsen ,  Abdulraouf Ramadan

IPC: A61K31/198 ,  A61K9/00 ,  A61K9/08 ,  A61K31/357 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K47/40 ,  A61P25/28 ,  A61P37/06 ,  C07C235/34 ,  C07D213/65 ,  C07D217/02 ,  C07D235/06 ,  C07D319/18

CPC classification number: A61K31/198 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/357 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K47/40 ,  A61P25/28 ,  A61P37/06 ,  C07C235/34 ,  C07D213/65 ,  C07D217/02 ,  C07D235/06 ,  C07D319/18

Abstract: Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:




wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.

公开(公告)号：US20230263760A1

公开(公告)日：2023-08-24

申请号：US18168128

申请日：2023-02-13

Applicant: Lapix Therapeutics, Inc.

Inventor： Anas M. Fathallah ,  Scott D. Larsen ,  Abdulraouf Ramadan

IPC: A61K31/198 ,  C07D217/02 ,  A61K47/40 ,  C07D213/65 ,  A61K31/357 ,  C07D235/06 ,  A61K9/08 ,  A61P37/06 ,  A61K9/00 ,  C07C235/34 ,  C07D319/18 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61P25/28

CPC classification number: A61K31/198 ,  C07D217/02 ,  A61K47/40 ,  C07D213/65 ,  A61K31/357 ,  C07D235/06 ,  A61K9/08 ,  A61P37/06 ,  A61K9/0053 ,  C07C235/34 ,  C07D319/18 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61P25/28

Abstract: Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:




wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.